DIA Biosimilars 2013

Saladax Biomedical

Saladax receives CLIA certification and approval

Friday, June 14, 2013 01:34 PM

Saladax Biomedical, a privately held company developing novel diagnostic tests that individually optimize a patient's exposure to chemotherapy, has been certified as a registered CLIA laboratory from the Office of Clinical Standards and Quality (OCSQ), a division of The Centers for Medicare & Medicaid Services (CMS) that regulates laboratory testing performed on humans. The CLIA certification and approval allows the company to begin clinical laboratory operations for the MyCare portfolio of products at its facilities in Bethlehem, Pa.

More... »

Cenduit: Now with Patient Reminders

Saladax Biomedical appoints Myslinski as CCO

Friday, November 16, 2012 12:18 PM

Saladax Biomedical, a Bethlehem, Penn.-based privately held company that develops diagnostic assays for the practical delivery of personalized medicine, has appointed Mark D. Myslinski as senior vice president and chief commercial officer.

More... »

CRF Health – eCOA Forum

Saladax Biomedical expands collaboration with BMS

Monday, August 6, 2012 12:23 PM

Saladax Biomedical, a developer of novel diagnostic assays, has expanded its existing relationship with Bristol-Myers Squibb by entering into a Master Early Development Collaboration Agreement, which may include multiple feasibility studies and companion diagnostic development projects. 

More... »

Saladax Biomedical names Harter president and CEO

Monday, June 18, 2012 11:35 AM

Saladax Biomedical, a Bethlehem, Penn.-based privately held company developing and commercializing novel diagnostic, has appointed Kevin M. Harter as president and chief executive officer.

More... »

CESAR and Saladax collaborate on a study of optimized 5-FU dosing in colorectal cancer patients

Tuesday, February 14, 2012 07:33 AM

Saladax Biomedical and the Central European Society for Anticancer Drug Research (CESAR) will be collaborating in a single-arm study of metastatic colorectal cancer patients treated with the chemotherapy drug 5-fluorouracil (5-FU).

More... »

CEPAC, Saladax enroll for non-small cell cancer study

Wednesday, April 27, 2011 01:40 PM

The Central European Society for Anticancer Drug Research (CESAR) in collaboration with Saladax Biomedical has begun enrollment in the CEPAC-TDM trial of paclitaxel therapeutic drug management (TDM) with subsequent pharmacokinetic-guided dose adjustment in patients being treated for advanced non-small cell lung cancer. 

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2013 CenterWatch.